Ataraxis is an AI precision medicine company transforming patient outcomes through the power of artificial intelligence. Backed by leading investors AIX Ventures, Floating Point, Bertelsmann Investments, Thiel Bio, Founders Fund, Giant Ventures, and Obvious Ventures, the company is addressing previously unsolvable problems in cancer prognosis and treatment selection through cutting-edge foundation models and multi-modal data. Ataraxis' first clinically validated offering, Ataraxis Breast, is the world's first AI-native prognostic/predictive platform for breast cancer and provides greater accuracy than standard of care genomic assays.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/06/25 | $20,400,000 | Series A |
AIX Ventures Bertelsmann Investments Floating Point Founders Fund Giant Ventures Mario Schlosser Obvious Ventures Ryan Fukushima Thiel Bio | undisclosed |
